Barr Labs confirms patent problem of Amrix extended-release capsules Barr Pharmaceuticals.

Amrix extended-launch capsules, 15mg and 30mg got annual sales of around $53 million in the U.S., predicated on IMS product sales data ending September 2008.. Barr Labs confirms patent problem of Amrix extended-release capsules Barr Pharmaceuticals, Inc. Provides verified that its subsidiary, Barr Laboratories, Inc., offers initiated a problem of the patent shown by Anesta regarding the its Amrix extended-launch capsules, 15mg and 30mg.Nine Months 2014 Outcomes AFFO for the nine weeks ended September 30, 2014 was $78.3 million, or $1.37 per talk about, in comparison to $58.6 million, or $1.28 per share, september 30 for the nine months ended, 2013, a rise of 7 percent. The development in AFFO per talk about was driven mainly by the Company's strong acquisition activity. Modified EBITDA for the nine weeks ended September 30, 2014 was $120.2 million, in comparison to $95.september 30 2 million for the nine months ended, 2013, a rise of 26 percent. Net gain for the nine a few months ended September 30, 2014 was $32.0 million, or $0.56 per talk about, in comparison to $12.0 million, or $0.26 per talk about, for the nine months ended September 30, 2013.